cgp74514

CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50=25 nM). This compound inhibits CDK1/cyclin B complex activity, resulting in G2/M phase cell cycle arrest and induction of tumor cell apoptosis, demonstrating promising applications in bladder cancer research.

CGP74514A is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor with an IC50 of 25 nM. It effectively inhibits the activity of the CDK1/cyclin B complex, arrests the cell cycle at G2/M phase, and further induces apoptosis in tumor cells, showing promising application prospects in bladder cancer research.

Potent cdk1 inhibitor (IC50 = 25 nM). Reduces Akt phosphorylation and increases mitochondrial damage in leukemia cells in vitro in combination with LY 294002. Yu et al (2013) The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 63 1822 PMID:12702569 |Furet et al (2000) Structure-based design of potent CDK1 inhibitors derived from olomoucine. J.Comput.Aided Mol.Des. 14 403 PMID:10896313

CGP-74514 dihydrochloride is a highly selective inhibitor of cyclin-dependent kinase 1 (CDK1) with an IC50 of 25 nM. It effectively suppresses the activity of the CDK1/cyclin B complex, halting the cell cycle at the G2/M phase and inducing apoptosis in tumor cells. This compound shows potential for bladder cancer research.